{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:53:54Z","timestamp":1768074834530,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To compare the long-term efficacy of corticosteroids (P) alone or in combination with cyclophosphamide (CTX), leflunomide (LEF), or Angiotensin-convertase inhibitors or angiotensin II receptor blockers (ACEI\/ARB) in treatment for IgA nephropathy (IgAN), 311 patients with IgAN were identified. Therapeutic effectiveness (including progression, partial remission, complete remission) and combined renal endpoint (defined as 30% reduction in eGFR or ESRD) were compared based on different therapies. After immunosuppressive and ACEI\/ARB treatment, the levels of eGFR, proteinuria and albumin were significantly improved at the last follow-up, the extent of improvement of eGFR, proteinuria, and albumin was more notable in P\u2009+\u2009CTX group and P\u2009+\u2009LEF group. 41%, 52.2%, 55.3% and 55.2% in P\u2009+\u2009CTX, P\u2009+\u2009LEF, P and ACEI\/ARB group achieved complete remission, respectively. Multivariate regression analysis indicated that only proteinuria (Relative risk (RR) 0.82(0.72\u20130.94), P\u2009=\u20090.004) and tubular atrophy\/interstitial fibrosis (RR 0.26(0.13\u20130.57), P\u2009=\u20090.001) were predictors for complete remission. The optimal cutoffs of eGFR was 47.085\u2009ml\/min\/1.73\u2009m<jats:sup>2<\/jats:sup> predicting renal function recovery in P\u2009+\u2009CTX therapy. In conclusion, tubular atrophy\/interstitial fibrosis and massive proteinuria were poor predictors for complete remission in IgAN, it appears as though patients may have benefited from immunosuppressive treatment but that comparison to a well-matched contemporary control group or, ideally, a randomized controlled clinical trial, would be required to show this.<\/jats:p>","DOI":"10.1038\/s41598-018-31727-5","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T09:40:24Z","timestamp":1536226824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study"],"prefix":"10.1038","volume":"8","author":[{"given":"Shasha","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-9979","authenticated-orcid":false,"given":"Guisen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,12]]},"reference":[{"key":"31727_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1523-1755.2004.00837.x","volume":"66","author":"LS Li","year":"2004","unstructured":"Li, L. S. & Liu, Z. H. Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies. Kidney International 66, 920\u2013923 (2004).","journal-title":"Kidney International"},{"key":"31727_CR2","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1681\/ASN.2005020134","volume":"16","author":"J Barratt","year":"2005","unstructured":"Barratt, J. & Feehally, J. IgA nephropathy. Journal of the American Society of Nephrology Jasn 16, 2088\u20132097 (2005).","journal-title":"Journal of the American Society of Nephrology Jasn"},{"key":"31727_CR3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt, R. J. & Julian, B. A. IgA nephropathy. New England Journal of Medicine 368, 2402\u20132414 (2013).","journal-title":"New England Journal of Medicine"},{"key":"31727_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","volume":"24","author":"G D\u2019Amico","year":"2004","unstructured":"D\u2019Amico, G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome \u2606. Seminars in Nephrology 24, 179\u2013196 (2004).","journal-title":"Seminars in Nephrology"},{"key":"31727_CR5","first-page":"503","volume":"18","author":"R Coppo","year":"2005","unstructured":"Coppo, R. & D\u2019Amico, G. Factors predicting progression of IgA nephropathies. Journal of Nephrology 18, 503\u2013512 (2005).","journal-title":"Journal of Nephrology"},{"key":"31727_CR6","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2011","unstructured":"Le, W. et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrology Dialysis Transplantation 27, 1479\u20131485 (2011).","journal-title":"Nephrology Dialysis Transplantation"},{"key":"31727_CR7","doi-asserted-by":"publisher","first-page":"e4731","DOI":"10.1097\/MD.0000000000004731","volume":"95","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA). Medicine 95, e4731 (2016).","journal-title":"Medicine"},{"key":"31727_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0467-z","volume":"18","author":"YH Song","year":"2017","unstructured":"Song, Y. H. et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. Bmc Nephrology 18, 61 (2017).","journal-title":"Bmc Nephrology"},{"key":"31727_CR9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2010010117","volume":"21","author":"C Pozzi","year":"2010","unstructured":"Pozzi, C. et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. Journal of the American Society of Nephrology Jasn 21, 1783 (2010).","journal-title":"Journal of the American Society of Nephrology Jasn"},{"key":"31727_CR10","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes, B. D. et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney International 65, 1842\u20131849 (2004).","journal-title":"Kidney International"},{"key":"31727_CR11","unstructured":"Ioannidis, J. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis \u2014 NEJM. New England Journal of Medicine (2014)."},{"key":"31727_CR12","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen, T. et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. New England Journal of Medicine 373, 2225\u20132236 (2015).","journal-title":"New England Journal of Medicine"},{"key":"31727_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5414\/CPP48509","volume":"48","author":"XW Liu","year":"2010","unstructured":"Liu, X. W., Li, D. M., Xu, G. S. & Sun, S. R. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. International Journal of Clinical Pharmacology & Therapeutics 48, 509 (2010).","journal-title":"International Journal of Clinical Pharmacology & Therapeutics"},{"key":"31727_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1440-1797.2006.00547.x","volume":"11","author":"T Lou","year":"2006","unstructured":"Lou, T. et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology 11, 113\u2013116 (2006).","journal-title":"Nephrology"},{"key":"31727_CR15","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1681\/ASN.2014070697","volume":"26","author":"V Tesar","year":"2015","unstructured":"Tesar, V. et al. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. Journal of the American Society of Nephrology Jasn 26, 2248\u20132258 (2015).","journal-title":"Journal of the American Society of Nephrology Jasn"},{"key":"31727_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi, C. et al. Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial. Journal of the American Society of Nephrology 15, 157\u2013163 (2004).","journal-title":"Journal of the American Society of Nephrology"},{"key":"31727_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv, J. et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation 53, 26 (2009).","journal-title":"American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation"},{"key":"31727_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14656566.2015.1005375","volume":"16","author":"L Tian","year":"2015","unstructured":"Tian, L. et al. The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up. Expert Opinion on Pharmacotherapy 16, 1\u201311 (2015).","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"31727_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine 150, 604\u2013612 (2009).","journal-title":"Annals of internal medicine"},{"key":"31727_CR20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ki.2009.168","volume":"76","author":"AWGOTIIN Network","year":"2009","unstructured":"Network, A. W. G. O. T. I. I. N. et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney International 76, 546\u2013556 (2009).","journal-title":"Kidney International"},{"key":"31727_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/ki.1993.259","volume":"44","author":"K Solez","year":"1993","unstructured":"Solez, K. et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney international 44, 411\u2013411 (1993).","journal-title":"Kidney international"},{"key":"31727_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","volume":"135","author":"GG Illei","year":"2001","unstructured":"Illei, G. G. et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Annals of Internal Medicine 135, 248\u2013257 (2001).","journal-title":"Annals of Internal Medicine"},{"key":"31727_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5414\/CPP48509","volume":"48","author":"XW Liu","year":"2010","unstructured":"Liu, X. W., Li, D. M., Xu, G. S. & Sun, S. R. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. Int J Clin Pharmacol Ther 48, 509\u2013513 (2010).","journal-title":"Int J Clin Pharmacol Ther"},{"key":"31727_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3892\/etm.2015.2860","volume":"11","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: A meta-analysis. Experimental & Therapeutic Medicine 11, 49 (2016).","journal-title":"Experimental & Therapeutic Medicine"},{"key":"31727_CR25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1053\/j.ajkd.2014.08.017","volume":"64","author":"LA Inker","year":"2014","unstructured":"Inker, L. A. et al. GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials. American Journal of Kidney Diseases 64, 848\u2013859 (2014).","journal-title":"American Journal of Kidney Diseases"},{"key":"31727_CR26","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","volume":"357","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti, P., Schieppati, A. & Remuzzi, G. Progression, remission, regression of chronic renal diseases. Lancet 357, 1601\u20131608 (2001).","journal-title":"Lancet"},{"key":"31727_CR27","first-page":"135","volume":"12","author":"KN Lai","year":"2015","unstructured":"Lai, K. N., Leung, J. C. & Tang, S. C. Recent advances in the understanding and management of IgA nephropathy. F1000 Research 12, 135\u2013147 (2015).","journal-title":"F1000 Research"},{"key":"31727_CR28","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMra020109","volume":"347","author":"JV Donadio","year":"2002","unstructured":"Donadio, J. V. & Grande, J. P. IgA nephropathy. New England Journal of Medicine 347, 738\u2013748 (2002).","journal-title":"New England Journal of Medicine"},{"key":"31727_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/ajkd.2000.8966","volume":"36","author":"G D\u2019Amico","year":"2000","unstructured":"D\u2019Amico, G. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors * **. American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation 36, 227\u2013237 (2000).","journal-title":"American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation"},{"key":"31727_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000168068","volume":"10","author":"O Bogensch\u00fctz","year":"1990","unstructured":"Bogensch\u00fctz, O. et al. IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. American Journal of Nephrology 10, 137\u2013147 (1990).","journal-title":"American Journal of Nephrology"},{"key":"31727_CR31","first-page":"77","volume":"5","author":"M Salvadori","year":"2016","unstructured":"Salvadori, M. & Rosso, G. Update on immunoglobulin a nephropathy.Part II:Clinical,diagnostic and therapeutical aspects. World Journal of Nephrology 5, 77\u201381 (2016).","journal-title":"World Journal of Nephrology"},{"key":"31727_CR32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","volume":"13","author":"FW Ballardie","year":"2002","unstructured":"Ballardie, F. W. & Roberts, I. S. D. Controlled Prospective Trial of Prednisolone and Cytotoxics in Progressive IgA Nephropathy. Journal of the American Society of Nephrology Jasn 13, 142\u2013148 (2002).","journal-title":"Journal of the American Society of Nephrology Jasn"},{"key":"31727_CR33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","volume":"18","author":"JA Tumlin","year":"2003","unstructured":"Tumlin, J. A., Lohavichan, V. & Hennigar, R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrology Dialysis Transplantation 18, 1321\u20131329 (2003).","journal-title":"Nephrology Dialysis Transplantation"},{"key":"31727_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10157-007-0497-0","volume":"11","author":"K Mitsuiki","year":"2007","unstructured":"Mitsuiki, K., Harada, A., Okura, T. & Higaki, J. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide. Clinical & Experimental Nephrology 11, 297\u2013303 (2007).","journal-title":"Clinical & Experimental Nephrology"},{"key":"31727_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ndt\/15.6.833","volume":"15","author":"D Roccatello","year":"2000","unstructured":"Roccatello, D. et al. Steroid and cyclophosphamide in IgA nephropathy. Nephrology Dialysis Transplantation 15, 833\u2013835 (2000).","journal-title":"Nephrology Dialysis Transplantation"},{"key":"31727_CR36","doi-asserted-by":"publisher","first-page":"c131","DOI":"10.1159\/000070232","volume":"93","author":"FM Rasche","year":"2003","unstructured":"Rasche, F. M. et al. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clinical Practice 93, c131\u2013c136 (2003).","journal-title":"Nephron Clinical Practice"},{"key":"31727_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00007890-199602270-00020","volume":"61","author":"KF Siemasko","year":"1996","unstructured":"Siemasko, K. F., Chong, A. S., Williams, J. W., Bremer, E. G. & Finnegan, A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61, 635\u2013642 (1996).","journal-title":"Transplantation"},{"key":"31727_CR38","doi-asserted-by":"publisher","first-page":"12398","DOI":"10.1074\/jbc.270.21.12398","volume":"270","author":"X Xu","year":"1995","unstructured":"Xu, X., Williams, J. W., Bremer, E. G., Finnegan, A. & Chong, A. S. F. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. Journal of Biological Chemistry 270, 12398\u201312403 (1995).","journal-title":"Journal of Biological Chemistry"},{"key":"31727_CR39","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1191\/096120301678416033","volume":"10","author":"CF Remer","year":"2001","unstructured":"Remer, C. F., Weisman, M. H. & Wallace, D. J. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10, 480\u2013483 (2001).","journal-title":"Lupus"},{"key":"31727_CR40","doi-asserted-by":"crossref","unstructured":"Cheng, G. et al. Valsartan combined with Clopidogrel and\/or Leflunomide for the treatment of progressive IgA nephropathy. Nephrology (2014).","DOI":"10.1111\/nep.12359"},{"key":"31727_CR41","doi-asserted-by":"crossref","unstructured":"Liu, Y. et al. Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: A meta-analysis. Experimental & Therapeutic Medicine 11 (2016).","DOI":"10.3892\/etm.2015.2860"},{"key":"31727_CR42","first-page":"935","volume":"61","author":"Y Kobayashi","year":"1986","unstructured":"Kobayashi, Y., Fujii, K., Hiki, Y. & Tateno, S. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Quarterly Journal of Medicine 61, 935\u2013943 (1986).","journal-title":"Quarterly Journal of Medicine"},{"key":"31727_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"GB Fogazzi","year":"1999","unstructured":"Fogazzi, G. B., Andrulli, S. & Altieri, P. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353, 883\u2013887 (1999).","journal-title":"Lancet"},{"key":"31727_CR44","doi-asserted-by":"publisher","first-page":"e18788","DOI":"10.1371\/journal.pone.0018788","volume":"6","author":"YH Zhou","year":"2011","unstructured":"Zhou, Y. H. et al. Steroids in the Treatment of IgA Nephropathy to the Improvement of Renal Survival: A Systematic Review and Meta-Analysis. Plos One 6, e18788 (2011).","journal-title":"Plos One"},{"key":"31727_CR45","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1681\/ASN.2011111112","volume":"23","author":"J Lv","year":"2012","unstructured":"Lv, J. et al. Corticosteroid therapy in IgA nephropathy. Journal of the American Society of Nephrology Jasn 23, 1108\u20131116 (2012).","journal-title":"Journal of the American Society of Nephrology Jasn"},{"key":"31727_CR46","doi-asserted-by":"crossref","unstructured":"Tesar, V. et al. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. Journal of the American Society of Nephrology 26 (2015).","DOI":"10.1681\/ASN.2014070697"},{"key":"31727_CR47","first-page":"174","volume":"26","author":"KN Lai","year":"1986","unstructured":"Lai, K. N., Lai, F. M., Ho, C. P. & Chan, K. W. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clinical Nephrology 26, 174\u2013180 (1986).","journal-title":"Clinical Nephrology"},{"key":"31727_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000226129","volume":"30","author":"J Cheng","year":"2009","unstructured":"Cheng, J. et al. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. American Journal of Nephrology 30, 315\u2013322 (2009).","journal-title":"American Journal of Nephrology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31727-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31727-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31727-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:31:04Z","timestamp":1671615064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31727-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31727"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31727-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,12]]},"assertion":[{"value":"12 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13662"}}